Page last updated: 2024-10-29

staurosporine aglycone and Parkinson Disease

staurosporine aglycone has been researched along with Parkinson Disease in 2 studies

staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Real, CC1
Ferreira, AF1
Chaves-Kirsten, GP1
TorrĂ£o, AS1
Pires, RS1
Britto, LR1
Wang, LH1
Besirli, CG1
Johnson, EM1

Reviews

1 review available for staurosporine aglycone and Parkinson Disease

ArticleYear
Mixed-lineage kinases: a target for the prevention of neurodegeneration.
    Annual review of pharmacology and toxicology, 2004, Volume: 44

    Topics: Alzheimer Disease; Animals; Carbazoles; Hearing Loss; Humans; Indole Alkaloids; Indoles; JNK Mitogen

2004

Other Studies

1 other study available for staurosporine aglycone and Parkinson Disease

ArticleYear
BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson's disease.
    Neuroscience, 2013, May-01, Volume: 237

    Topics: Analysis of Variance; Animals; Apomorphine; Carbazoles; Corpus Striatum; Disease Models, Animal; Enz

2013